Drug Profile

RTX 001 - Resolution Therapeutics

Alternative Names: RTX-001 - Resolution Therapeutics

Latest Information Update: 18 Nov 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Resolution Therapeutics
Class Anti-inflammatories; Antifibrotics; Cell therapies; Gene therapies
Mechanism of Action Macrophage replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase II Liver cirrhosis

Most Recent Events

07 Nov 2025 Pharmacodynamics data from a preclinical trials in Liver cirrhosis released by Resolution Therapeutics
07 Nov 2025 Updated efficacy data from a phase II MATCH trial in Liver cirrhosis released by Resolution Therapeutics
19 Nov 2024 Resolution Therapeutics plans the phase I/II EMERALD trial for Liver cirrhosis in Spain (IV) in the second quarter of 2025

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com